Conference Day One
Wednesday, July 31 2024
7:30 am Morning Check-in & Light Breakfast
8:20 am Chair’s Opening Remarks
Recapping the Busy Year for Radiopharmaceuticals: Current Status & Future Perspectives
8:30 am Panel Discussion: Reflecting on the Past Year- Discussing Current Radiopharmaceutical Trends & Assessing Our Progress
Synopsis
- Exploring PSMA updates and predictions for the future market of prostate cancer drugs
- Pricing and reimbursement considerations in a competitive market
- Discussing key future commercial challenges and opportunities for the field from advances in manufacturing to competitive demand and selection of radioisotopes, with emphasis on actinium-225, lead-212, copper-64
9:15 am Revealing Results of Phase Three Randomized NETTER-2 Novartis Trial to Explore a First Line Treatment for NET
Synopsis
- To discuss the results of the NETTER 2 clinical trial
- To review the current use of RLT in first line treatment of cancer
- To understand the role of RLT in aggressive NET disease
9:45 am Session Reserved for Late Breaking Abstract
10:15 am Speed Networking & Refreshments
Discovery & Preclinical
Exploring New Radioisotope Targeting Technologies to Optimize Your Molecule
11:45 am Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/ Refractory AML Using Antibody Radiation Conjugates (ARC)
Synopsis
- Exploring Iomab-B, a CD45 I-131 ARC, enables bone marrow transplant in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
- Outlining how responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutant disease, demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
- Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response
12:15 pm Session Reserved For Applied Biomath
12:45 pm Revealing Pretargeting for 177Lu/225Ac Dual-Isotope Therapy of Colorectal Cancer
Synopsis
- Pretargeting as a suitable approach for efficient and controlled tandem-radiotherapy
- Confirming co-localization of 225Ac- and 177Lu-labeled radiohaptens with autoradiography using iQID
- Pretargeted 177Lu/225Ac dual-isotope therapy can be safely administered at potentially curative doses (62.9 GBq/kg 177Lu + 2 MBq/kg 225Ac) in mice
Early-Stage Clinical
Securing Translational Success Through Forward Thinking Nuclear Clinical Design
11:45 am Considerations for Designing an Optimal First in Human Radiopharmaceutical Trial
Synopsis
- Evolving strategy and lessons learned from moving from lab to clinic
- From ADC to RPT, our lessons learned about FIH study design dynamics about safety, dosimetry and PK/PD from Th227 to Ac225
- Engaging with multidisciplinary teams: internal and external stakeholders (NM physicians, imaging and radiopharmacists, regulatory)
12:15 pm Roundtables: Sharing Learnings from Translating to the Clinic & Setting up your First Radiopharmaceutical Tria
Synopsis
- Hearing firsthand perspectives from designing and moving into the clinic
- Using predictive analysis for clinical design
- Exploring lessons learned from challenges along the way
12:45 pm Outlining a Best-in-class SST2 Antagonist in SCLC & a Cancer Cell DNA Targeted- Auger-Electron Approach in Solid Tumors
Synopsis
- Using Satoreotide, aka JR11, labelled with Lu, Ac or Tb in SCLC
- Understanding the impact of changing tracer versus changing isotope
- Introducing a radioactively labelled small molecule to target tumor cell DNA using Auger emitters
Late-Stage Clinical
Late-Stage Updates & Learnings to Inform Future Radioisotope Development
11:45 am Clinical Advances of 225Ac-targeted Antibody & Small Molecule-based Agents & Revealing Preclinical Insights from Immune Checkpoint Combination Approaches
Synopsis
- Outlining why 225Ac is an attractive radioisotope for targeted therapy
- Exploring clinical strategy and updates on Fusion’s antibody and small molecule programs, including FPI-2265 (a phase 2/3 study)
- Revealing rational drug combinations for targeted alpha therapeutics
12:15 pm Roundtables: Looking Toward Potential Latent Toxicities for PSMA TRPs
Synopsis
- As more patients are receiving PSMA radiopharmaceuticals, more monitoring is required
- Examining radiation dose and potential secondary malignancies
- Discussing preventative steps
12:45 pm Designing Successful Clinical Trials for Commercial Success & Patient Access
Synopsis
- Outlining key strategies to executing effective clinical trials and bringing life-changing, potentially life-saving products to market faster
- Examining why successfully executed clinical trials fail to deliver drugs to patients
- Improving clinical trial design and performance, as well as thinking beyond trial outcomes to facilitate the success of products throughout their development lifecycles
1:15 pm Lunch Break & Networking
Discovery & Preclinical
Creating the Perfect Blend of Novel Payload & Targeting Approaches to Expand Specificity
2:15 pm Panel Discussion: Examining Radiobiology & Differences in Immunological Responses Between Alpha & Beta Nuclides
Synopsis
- Discussing what responses have been observed to different isotopes and isotope combinations
- Exploring optimal use for each
- Looking toward future development opportunities
2:45 pm Innovation Spotlight
Synopsis
Your chance to see the latest technologies being applied to preclinical radiopharmaceutical development.
Observe and get to know 3 innovative new solutions in this lightning-round technical demonstration.
3:00 pm Towards Optimizing Tumor Retention of FAP-Targeting Theranostics
Synopsis
- Discussing the promise of FAP as a target for the imaging and therapy of various solid tumors
- Summarizing approaches used in the FAP field for optimizing tumor AUC
- Exploring insights into Actithera’s approaches and molecules
Early-Stage Clinical
Applying Dosimetry to Early Studies to Enhance Clinical Understandings
2:15 pm Panel Discussion- Integrating Dosimetry into Early-Stage Clinical Trials
Synopsis
- Exploring how dosimetry should be incorporated
- Looking at best practices for scans with treatment cycles
- Uncovering how often should scans occur?
2:45 pm Session Reserved For Trasis
3:00 pm Examining Dosimetry Data in Alpha Emitters: Similarities & Differences
Synopsis
- Exploring differences in alpha vs beta dosimetry analysis from clinical perspective
- Can administered activity predict the outcome?
- How to personalize the radiopharmaceuticals prescription beyond dosimetry?
Late-Stage Clinical
Supply Chain & Manufacturing- Learning from Late-Stage Production While Navigating Future Challenges
2:15 pm Advancing Isotope Evaluation & Quality Control Methods for Radiopharmaceutical Manufacturing
Synopsis
- Navigating radiopharmaceutical production with emerging isotopes
- Dealing with concatenated decay is significantly more challenging than for previous diagnostic agents
- Discussing new tools and insights that are being developed and leveraged to improve formulation and quality control for optimal use in the clinical setting
2:45 pm Session Reserved For Shine
3:00 pm Panel Discussion: Scaling Up – Lessons Learned from Increasing Commercial Supply
Synopsis
- Identifying process optimization to address bottlenecks
- Expanding robust supply chain management for highly trained nuclear manufacturing professionals
- Navigating regulatory compliance
3:30 pm Afternoon Break & Networking
Uncovering Novel Targets for Therapeutic Applications & Bridging the Gap Between Sponsors & Patient Communities
4:00 pm LRRC15-Targeted Radiotheranostic Strategies to Overcome TGFB-Driven Treatment Resistance in Cancer
Synopsis
- Exploring novel strategies for overcoming radioresistance
- Outlining novel target
- Applications to broader therapies
4:30 pm Session Reserved For ITM
5:00 pm Sharing How to Engage the Patient Community in Research: Real World Experience Form a Research Advocate
Synopsis
- Outlining how to engage patients early on in your trial
- Using patient advocates to optimize clinical trial design
- Exploring how to approach patients for engagement